Organisation mondiale de la santé (OMS) · Technical Documents

Polio Bulletin - 2015, Issue no. 05 (Week 11)

16 mars 2015 Organisation mondiale de la santé

Le texte intégral est hébergé par l’organisation qui le publie. lawenc.com indexe les métadonnées et renvoie vers la source officielle.

Texte intégral

2015 Issue No. 5 - Week 11 (as of 16 March 2015) HIGHLIGHTS Excerpt from the WHO Statement on the Fourth Meeting of the International Health Regulations Emergency Committee regarding the International Spread of Wild Poliovirus, 27 February 2015 The fourth meeting of the Emergency Committee under the International Health Regulations (IHR) (2005) regarding the international spread of wild poliovirus in 2014–15 was convened via teleconference by the Director-General on 17 February 2015. The Committee noted that the international spread of wild poliovirus has continued with one new exportation from Pakistan into neighbouring Afghanistan documented after 13 November 2014. There has been no other documented international spread of wild poliovirus since March 2014. The Committee assessed that the spread of polio still constitutes a Public Health Emergency of International Concern and recommended the extension of the Temporary Recommendations for a further three months. Specific recommendations were made to States currently exporting wild poliovirus including Cameroon (until 11 March), Equatorial Guinea (Until 4 April), Syrian Arab Republic (until 17 March) and Pakistan; States infected with wild poliovirus but not currently exporting including Afghanistan, Nigeria, Somalia, Ethiopia (until 16 March), Iraq (until 19 May), and Israel (until 28 April); and States no longer infected by wild poliovirus, but which remain vulnerable to international spread including Ethiopia by 16 March, in Syria by 17 March, in Israel by 28 April, and in Iraq by 19 May should there be no further detection of wild poliovirus in these countries. 3.0

Polio Bulletin

Chart 1. Non-polio AFP rate (per 100 000 persons < 15 years of age), 2013–2015* 100%

Chart 2. Adequate specimen collection rate, 2013–2015

2.5

80%

2.0 60%

1.5 40%

1.0 20%

0.5

0.0 13 14 CHN 15 13 14 KHM 15 13 14 LAO 15 13 14 MYS 15 13 14 PHL 15 13 14 PNG 15 13 14 VNM 15

0% 13 14 CHN 15 13 14 KHM 15 13 14 LAO 15 13 14 MYS 15 13 14 PHL 15 13 14 PNG 15 13 14 VNM 15

* AFP rate annualized as of week 11

Chart 3. Percentage of reported AFP cases by number of polio vaccination doses, 2015 100%

Chart 4. Percentage of reported AFP cases with pending classification > 90 days after onset, 2015 CHN

80%

KHM LAO MYS

60%

40%

PHL PNG VNM

20%

CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: WPR_EPIdata@wpro.who.int Web: www.wpro.who.int/immunization 0% CHN KHM LAO MYS 1-2 doses

PHL 0 doses

PNG Unknown

VNM

20%

40%

60%

80%

100%

≥ 3 doses

Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).

Table 1A. Classification of AFP cases with onset in 2014 and key surveillance indicators 2013 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with % with investigated adequate 60-day 2 days of ≤ 4 specimens 2 3 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date 5 Days since last report 6

2014 Indicators

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries and areas Total 1. 2. 3. 4. 5. 6.

62 1 73 5623 12 1 0 48 155 7 12 18 277 84 7 459 8 6847

44 1 46 2225 8 1 167 25 77 8 9 30 378 72 6 231 10 3338

61 4 72 5811 19 1 0 28 161 9 8 12 277 88 8 358 14 6931

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

57 2 68 5284 19 1 27 161 9 8 11 236 88 8 293 9 6281

4 2 4 527 0 0 1 0 0 0 1 40 0 0 65 5 649

3 (4.9%) 0 (0.0%) 1 (1.4%) 332 (5.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 34 (12.3%) 0 (0.0%) 0 (0.0%) 24 (6.7%) 5 (35.7%) 399 (5.8%) Green Yellow Red

1.39 4.00 1.57 2.61 2.38 1.00 1.12 2.09 1.13 0.89 0.40 0.73 1.22 1.33 1.55 1.40 2.08

44% 75% 96% 92% 89% 0% 57% 73% 89% 38% 33% 59% 86% 75% 97% 64% 90%

84% 100% 93% 100% 100% 100% 93% 87% 100% 100% 75% 97% 98% 88% 93% 93% 99%

0% 100% 67% 95% 100% 100% 83% 100% 100% 80% 0% 6% 100% 100% 100% 80% 76%

20-Feb-15 07-Feb-15 16-Feb-15 12-Mar-15 05-Mar-15 13-Jan-15 04-Feb-15 10-Mar-15 05-Mar-15 11-Mar-15 04-Mar-15 12-Mar-15 16-Feb-15 07-Jan-15 04-Feb-15 27-Jan-15

24 37 28 4 40 12 4 40 48

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens for which the 60-day follow-up evaluation has been completed Report date is fixed as soon as all cases for the year have been classified Countries are expected to submit data at least once per month to WPRO

Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target

Polio Bulletin

Table 1B. Classification of AFP cases with onset in 2015 and key surveillance indicators 2014 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate 2 % % with % with investigated 60-day adequate 2 days of ≤ 5 specimens 3 4 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date Days since last report 6

2015 Indicators

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

61 4 72 5811 19 1 0 28 161 9 8 12 277 88 8 358 14 6931

44 1 46 2225 8 1 167 25 77 8 9 30 378 72 6 231 10 3338

2 0 4 507 2 0 0 0 22 1 1 2 47 7 2 0 1 598

0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 32 1 1 0 0 0 0 2 2 0 38

2 4 475 1 21 1 1 2 47 5 0 1 560

0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%) 1 (0.2%) Green Yellow Red

0.21 0.41 1.08 1.18 1.35 0.59 0.53 0.32 0.59 0.46 1.58 0.47 0.85

0% 100% 94% 100% 86% 100% 100% 100% 51% 86% 100% 0% 90%

100% 100% 100% 100% 50% 100% 100% 50% 98% 100% 100% 0% 97%

0% 11% 33% 0% 0% 0% 7%

20-Feb-15 05-Feb-15 09-Feb-15 12-Mar-15 05-Mar-15 12-Mar-15 04-Feb-15 10-Mar-15 05-Mar-15 11-Mar-15 02-Mar-15 12-Mar-15 16-Feb-15 02-Mar-15 09-Feb-15 27-Jan-15

24 39 35 4 11 4 40 6 11 5 14 4 28 14 35 48

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Annualized non-polio AFP rate per 100 000 population under 15 years of age Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens for which the 60-day follow-up evaluation has been completed Countries are expected to submit data at least once per month to WPRO

Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target

Polio Bulletin

Table 2A. Laboratory investigation of AFP cases with onset in 2014 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases w ith specimens positive L20B positive + NPEV NPEV only Pending ≤ 14 Negative days % % results Latest Pending reported specimens positive report date > 14 2 ≤ 14 days for NPEV days ≥ 80% Intratypic differentiation/ Sequencing lab 1 No. of isolates received Type 1 Wild Sabin VDPV Wild Intratypic differentiation (ITD)/sequencing results Type 3 Type 2 Sabin VDPV Wild Sabin VDPV NPEV 3

Pending ITD

% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%

Australia Brunei Darussalam Cambodia China China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam (North) Viet Nam (South) Pacific island countries and areas Total

VIDRL VIDRL NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC NIID NIID IMR PHI IESR VIDRL RITM NIH SGH NIHE PI VIDRL

45 2 73 5740 332 40 213 132 355 278 331 150 536 267 319 190 54 103 397 29 230 414 26 103 267 189 73 205 43 186 137 87 31 21 2 19 0 0 25 164 9 5 10 342 88 8 216 136 12 6894

0 0 5 110 20 1 2 0 4 6 10 2 4 4 18 2 1 1 5 2 4 4 0 1 11 2 0 0 0 2 1 1 2 0 0 0 1 0 0 0 0 5 0 0 0 0 0 121

0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 3

2 0 12 584 26 0 27 11 47 56 37 7 61 36 3 27 7 4 39 0 2 42 3 5 38 20 14 24 7 23 11 3 0 4 0 4 5 4 1 1 4 13 8 0 30 16 1 685

43 2 56 5021 284 39 184 121 304 214 283 141 470 222 298 160 46 97 352 27 221 366 23 94 218 167 59 181 36 161 123 82 29 17 2 15 19 160 8 4 5 324 80 8 186 120 11 6062

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 24 2 0 0 0 0 2 0 0 1 5 0 1 0 1 1 0 3 2 0 3 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 24

96% 50% 96% 75% 83% 81% 92% 80% 81% 64% 69% 89% 80% 90% 79% 92% 66% 87% 83% 98% 55% 42% 92% 96% 51% 69% 71% 91% 76% 60% 85% 65% 76% 93% 67% 93% 100% 100% 100% 91% 100% 88% 97% 100% 100% 93% 100%

2% 0% 14% 9% 7% 0% 10% 7% 11% 16% 8% 4% 9% 13% 1% 13% 11% 4% 7% 0% 1% 9% 10% 4% 11% 8% 15% 11% 14% 12% 7% 2% 0% 17% 0% 11% 18% 2% 11% 18% 50% 3% 10% 0% 12% 11% 4%

22-Jan-15 22-Jan-15 02-Feb-15 12-Mar-15

VIDRL VIDRL NIID Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC

0 0 10 307 45 11 3 6 9 12 11 6 6 4 44 4 4 2 8 6 12 10 10 6 24 8 4 13 0 6 19 8 6 0 0 0 0 0 0 0 0 0 4 13 2 0 0 0 0 336

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 72 10 3 0 2 4 0 2 0 1 2 7 1 1 0 3 0 2 4 2 4 7 0 0 0 4 9 4 0 0 4 0 76

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

10 106 14 1 0 2 3 7 6 2 2 2 15 0 1 2 3 2 6 4 4 2 7 2 2 7 0 4 2 4 0 6 0 122

0 4 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 5

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 113 21 7 3 2 2 5 1 3 3 0 17 1 2 0 2 4 2 2 4 0 10 4 2 6 2 4 2 2 2 2 0 117

0 2 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2

0 7 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 0 2 0 0 0 2 0 0 2 0 2 11

0 3 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

100% 95% 91% 100% 100% 100% 78% 100% 100% 100% 75% 100% 97% 100% 100% 100% 100% 100% 90% 100% 100% 100% 93% 100% 100% 82% 100% 100% 100% 100% 100% 100% 100% 96%

13-Jan-15 13-Jan-15 22-Jan-15 10-Feb-15 16-Mar-15 12-Jan-15 22-Jan-15 11-Mar-15 16-Feb-15 14-Jan-15 11-Feb-15 21-Jan-15 22-Jan-15

PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

1. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells

Polio Bulletin

Table 2B. Laboratory investigation of AFP cases with onset in 2015 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with specimens positive L20B positive + NPEV NPEV only Pending ≤ 14 Negative days % % results Latest Pending reported specimens positive report date > 14 2 ≤ 14 days for NPEV days ≥ 80% Intratypic differentiation/ Sequencing lab 1 No. of isolates received Type 1 Wild Sabin VDPV Wild Intratypic differentiation (ITD)/sequencing results Type 3 Type 2 Sabin VDPV Wild Sabin VDPV NPEV 3

Pending ITD

% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%

1 1 4 500 22 5 17 5 35 21 28 8 50 23 30 9 7 10 40 6 15 51 12 6 16 32 7 13 5 11 11 4 1 0 0 1 0 0 4 16 1 0 2 128 7 2 17 10 0 694

0 0 0 7 0 0 0 0 1 0 1 0 1 0 1 1 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 15 0 0 2 0 18

1 1 4 451 17 5 17 5 34 21 27 6 49 22 27 7 7 0 40 6 14 40 11 4 14 28 6 12 5 11 11 4 1 0 4 15 1 1 103 3 2 14 9 609

0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 9 4 0 1 1 18

0 0 0 41 5 0 0 0 0 0 0 2 0 1 2 1 0 10 0 0 1 11 0 2 1 3 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 42

0% 100% 100% 96% 100% 100% 94% 100% 100% 100% 98% 100% 92% 100% 91% 100% 100% 100% 100% 71% 98% 100% 100% 100% 86% 100% 92% 100% 91% 100% 100% 100% 100% 100% 50% 100% 92% 100% 100% 100% 89% 96%

0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 3% 0% 0% 10% 0% 0% 10% 0% 0%

02-Mar-15 02-Mar-15 23-Feb-15 12-Mar-15

0 0 0 11 0 2 0 0 2 0 0 0 1 0 0 2 0 0 0 0 0 0 2 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 11

0 0 0 0 0 0 0 0 0

4 0 2 1 0 0 1 0 4

0 0 0 0 0 0 0 0 0

4 2 0 0 2 0 0 0 4

0 0 0 0 0 0 0 0 0

3 0 0 0 0 2 0 1 3

0 0 0 0 0 0 0 0 0

78% 0% 100% 100% 100% 100% 100% 100% 78%

04-Feb-15 04-Feb-15 09-Mar-15 11-Mar-15 10-Mar-15 05-Mar-15 02-Mar-15 11-Mar-15 16-Feb-15 14-Feb-15 12-Mar-15 12-Mar-15 02-Mar-15

CCDC CCDC PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

Polio Bulletin

Table 3A. Laboratory confirmation of polio isolates from other sources in 2014 Non-AFP cases Country Intratypic differentiation lab 2 Total number Total number of non-AFP of non-AFP cases tested cases with for polio polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin VDPV Pending NPEV ITD Discordant Total number pending of samples sequencing processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV

Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 NPEV Sabin VDPV Pending ITD Discordant pending sequencing

96 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 203 0 0 3 0 0 0 0 0 305

0 3 1 2 0 3 6

0 0 0 0 0 0 0

0 3 1 2 0 1 4

0 0 0 0 0 0 0

0 0 0 0 0 1 1

0 0 0 0 0 0 0

0 1 0 1 0 1 2

0 0 0 0 0 0 0

0 0 0 0 23 0 23

0 0 0 0 0 0 0

3 0 0 167 0 0 14 0 48 0 0 18 0 0 0 0 0 0 48 12 0 0 0 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 191

0 167 14 48 18 48 12 27 7 174

0 0 0 0 0 0 0 0 0

79 1 21 11 13 6 27 1 80

0 0 0 0 0 0 0 0 0

129 4 22 37 16 12 38 1 130

2 0 0 1 0 0 1 0 2

0 0 0 0 0 0 0 0 0

115 0 15 47 23 10 20 5 120

0 0 0 0 0 0 0 0 0

3 0 0 0 0 0 0 0 7 10

0 0 0 0 0 0 0 0 0 0

1. Based on year of collection of sample, if available. Otherw ise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Polio Bulletin

Table 3B. Laboratory confirmation of polio isolates from other sources in 2015 Non-AFP cases Country Intratypic differentiation lab 2 Total number Total number of non-AFP of non-AFP cases tested cases with for polio polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin VDPV Pending NPEV ITD Discordant Total number pending of samples sequencing processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV

Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 NPEV Sabin VDPV Pending ITD Discordant pending sequencing

23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 26 0 0 2 0 0 0 0 0 51

0 0 2 2

0 0 0

0 1 1

0 0 0

0 1 1

0 0 0

0 2 0 2

0 0 0 0

8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8

1 1

0 0

1 1

0 0

5 5

0 0

1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)

Polio Bulletin

Table 4. Vaccine-derived poliovirus, 2000–2015 Country Cambodia

2000–2009

2010

2011

2012

2013

2014

2015

2006 (1 case) Total (2 cases) 2009 (1 case) Total (27 cases) 2005 (3 cases) 2005 (1 case) Total (2 cases) 2004 (3 cases) 2003 (1 case) 2001 (3 cases) aVDPV2 (2 cases) ?VDPV2 (1 case) aVDPV2 (5 cases) aVDPV3 (2 cases) aVDPV1 (1 case) aVDPV2 (3 cases) cVDPV2 (2 cases) iVDPV2 (2 cases) iVDPV3 (1 case) aVDPV1 (1 case) aVDPV2 (2 cases) aVDPV2 (1 case) cVDPV2 (3 cases) iVDPV2 + iVDPV3 (1 case) iVDPV2 + iVDPV3 (1 case) aVDPV2 (2 cases) iVDPV3 (1 case) aVDPV1 (1 case)

China China, Hong Kong SAR Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam

1. Prefix letter refers to the VDPV category - "cVDPV" = circulating VDPV, "iVDPV" = immunodeficiency-associated VDPV, "aVDPV" = ambiguous VDPV, "?VDPV" = unknown. Suffix number refers to the poliovirus serotype (types 1, 2 or 3). 2. Refers to year of last VDPV case, and aggregate total of VDPV cases for 2000-2009

Polio Bulletin

Informations clés

Organisation Organisation mondiale de la santé (OMS)

Type de document Technical Documents

Date d'adoption 16 mars 2015

Source Organisation mondiale de la santé